2023-2030 年大分子药物 CDMO 行业分析、规模、份额、增长、趋势和预测的全球市场研究报告

全球对大分子药物CDMO市场的需求将从2022年的227.1亿美元增长到2030年的约579.4亿美元，2023年至2030年调查期间复合年增长率为12.42%，预计将达到

大分子药物 CDMO 是合同开发和製造组织 (CDMO)，提供加工大分子药物的服务。 大分子高度复杂，具有治疗作用，并且製备得与人类蛋白质相似。 它是分子製造的关键步骤之一。 我们通过为客户提供从药物开发到製造的服务来支持製药行业。 CDMO 通过提供知识、开发和製造能力以及整合第三方项目来提供基本服务。

市场动态：

推动大分子CDMO市场需求的主要因素是传染病患者的增加。 FDA 对大分子药物的批准增加有助于该市场的增长。 由于慢性病的增加，对药品的需求不断增长，这推动了市场需求。 预计在预测期内，技术的不断进步、资本投资的增加以及製药和生物技术公司与 CDMO 之间合作伙伴关係的建立将为该市场带来若干增长机会。 与生物製剂和生物仿製药相关的研发活动的增加正在增加对该市场的需求。 心血管疾病和 CVD 死亡率的增加推动了对该市场的需求。 然而，严格的政府法规可能会阻碍该市场的增长。

这份研究报告描述了波特的五力模型、市场吸引力分析和价值链分析。 这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。 此外，这些工具还能够全面评估全球大分子原料药cdmo市场的各个细分市场。 大分子药物 cdmo 行业的增长和趋势为这项研究提供了一个整体方法。

市场细分：

本部分提供按国家和地区细分的详细数据，以帮助您确定您的产品或服务的目标受众和未来商机。

按服务

• 合同製造（临床、商业）
• 合同开发（细胞系开发、工艺开发）

按供应商

• 哺乳动物
• 微生物
• 其他

由最终用户

• 生物技术公司
• 首席风险官
• 其他

按地区分析：

本节提供了北美、欧洲、亚太地区、拉丁美洲、中东和非洲对大型原料药 CDMO 市场当前和未来需求的区域展望。 它还侧重于所有主要地区的各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。 大分子药物 cdmo 市场的主要参与者是 Eurofins Scientific、WuXi Biologics、Samsung Biologics、Catalent, Inc、Rentschler Biopharma SE、AGC Biologics、Recipharm AB、Siegfried Holding AG、Boehringer Ingelheim 和 Fujifilm Diosynth Biotechnologies。 本节概述了竞争格局，包括各种战略发展，例如主要併购、未来能力、合作伙伴关係、财务概览、合作、新产品开发和新产品发布。

如果您有定制要求，请联繫我们。 我们的研究团队可以根据您的需要提供定制报告。

内容

第一章前言

• 本报告的内容
  • 目的
  • 目标受众
  • 独特的销售建议 (USP) 和提供的服务
• 调查范围
• 调查方法
  • 市场调研过程
  • 市场研究方法

第 2 章执行摘要

• 市场亮点
• 全球市场概况

第三章大分子药物CDMO-产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场製约因素
• 市场机会
• 行业趋势
• 波特的五力分析
• 市场吸引力分析
  • 按服务分类的市场吸引力分析
  • 按来源进行市场吸引力分析
  • 按市场进行的吸引力分析：按最终用户
  • 市场吸引力分析：按地区

第四章价值链分析

• 价值链分析
• 原材料分析
  • 成分錶
  • 原材料製造商列表
  • 主要原材料价格走势
• 潜在买家名单
• 营销渠道
  • 直接营销
  • 间接营销
  • 营销渠道趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章大分子 CDMO 的全球市场分析：按服务分类

• 服务概览
• 实际数据和预测数据
• 服务分析
• 合同製造（临床、商业）
• 委託开发（细胞系开发、工艺开发）

第 7 章全球大分子 CDMO 市场分析：按供应商

• 按来源汇总
• 实际数据和预测数据
• 来源分析
• 哺乳动物
• 微生物
• 其他

第 8 章大分子药物 CDMO 的全球市场销售分析：按最终用户分类

• 最终用户总结
• 实际数据和预测数据
• 最终用户分析
• 生物技术公司
• 首席风险官
• 其他

第9章大分子原料药cdmo全球市场销售分析：按地区

• 按地区进行的销售分析
• 介绍销售分析
• 北美销售分析
  • 概览、历史和预测销售分析
  • 北美各部门的销售分析
  • 北美销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史和预测销售分析
  • 按细分市场进行的欧洲销售分析
  • 按国家/地区划分的欧洲销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 意大利销售分析
  • 俄罗斯销售分析
  • 其他欧洲销售分析
• 亚太地区销售分析
  • 概览、历史和未来销售分析
  • 亚太地区各部门的销售分析
  • 亚太国家/地区销售分析
  • 在中国的销售分析
  • 印度销售分析
  • 日本的销售分析
  • 韩国销售分析
  • 澳大利亚销售分析
  • 其他亚太地区销售分析
• 拉丁美洲销售分析
  • 概览、历史和未来销售分析
  • 拉丁美洲各部门的销售分析
  • 拉丁美洲国家/地区的销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利的销售分析
  • 其他拉丁美洲销售分析
• 中东和非洲销售分析
  • 概览、历史和未来销售分析
  • 中东/非洲地区的销售分析
  • 中东和非洲国家/地区的销售分析
  • 沙特阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 其他中东和非洲销售分析

第10章高分子药物CDMO企业竞争格局

• 大分子原料药 Cdmo 的市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第11章公司简介

• 前 10 名公司的市场份额分析
• 市场集中度
• 欧陆科学
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期发展状况
• 药明生物
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 三星生物製品
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 康泰伦特公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Rentschler Biopharma SE
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• AGC 生物製剂
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Recipharm AB
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 齐格弗里德控股公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 勃林格殷格翰
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Fujifilm Diosynth Biotechnologies
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期趋势

注意：公司简介中的财务细节和近期发展基于可用信息，可能不包括私营公司。

The global demand for Large Molecule Drug Substance CDMO Market is presumed to reach the market size of nearly USD 57.94 BN by 2030 from USD 22.71 BN in 2022 with a CAGR of 12.42% under the study period 2023 - 2030.

Large molecule drug substance CDMO refers to the contract development and manufacturing orGaNizations (CDMO) which provide services for processing large molecule drug substances. Large molecules are highly complex, have therapeutic effects and are prepared to resemble human proteins. It is one of the important steps for molecule production. It provides customers with services from drug development to manufacturing and, thus, assists the pharmaceutical industry. CDMO offers knowledge, development and manufacturing capabilities and provides crucial services by incorporating third-party projects. 

Market Dynamics:

The key factor driving the demand for large molecule drug substance CDMO market is the rising cases of infectious diseases. Increasing large molecule drug approvals with FDA are contributing to the growth of this market. The growing pharmaceutical products demand due to the rising incidence of chronic diseases is surging the demand for this market. Continuous advancement in technology, increasing capital investment and establishment of partnerships by Pharma as well as biotech firms with CDMOs are expected to create several growth opportunities for this market over the forecast period. The rise in research and development activities associated with biologics and biosimilars is augmenting the demand for this market. Growth in cardiovascular diseases and CVD-induced deaths propel the demand for this market. However, stringent government regulations may obstruct the growth of this market. 

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of large molecule drug substance cdmo. The growth and trends of large molecule drug substance cdmo industry provide a holistic approach to this study. 

Market Segmentation:

This section of the large molecule drug substance cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Service

• Contract Manufacturing (Clinical, Commercial)
• Contract Development (Cell Line Development, Process Development)

By Source

• Mammalian
• Microbial
• Others

By End-User

• Biotech Companies
• CRO
• Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Large Molecule Drug Substance CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the large molecule drug substance cdmo market include Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . LARGE MOLECULE DRUG SUBSTANCE CDMO - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Service
  • 3.7.2 Market Attractiveness Analysis By Source
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SERVICE

• 6.1 Overview by Service
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Service
• 6.4 Contract Manufacturing (Clinical, Commercial) Historic and Forecast Sales by Regions
• 6.5 Contract Development (Cell Line Development, Process Development) Historic and Forecast Sales by Regions

7 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SOURCE

• 7.1 Overview by Source
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Source
• 7.4 Mammalian Historic and Forecast Sales by Regions
• 7.5 Microbial Historic and Forecast Sales by Regions
• 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET SALES ANALYSIS BY END-USER

• 8.1 Overview by End-user
• 8.2 Historical and Forecast Data
• 8.3 Analysis by End-user
• 8.4 Biotech Companies Historic and Forecast Sales by Regions
• 8.5 CRO Historic and Forecast Sales by Regions
• 8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET SALES ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook Sales Analysis
• 9.2. Introduction Sales Analysis
• 9.3. North America Sales Analysis
  • 9.3.1. Overview, Historic and Forecast Sales Analysis
  • 9.3.2. North America By Segment Sales Analysis
  • 9.3.3. North America By Country Sales Analysis
  • 9.3.4. United State Sales Analysis
  • 9.3.5. Canada Sales Analysis
  • 9.3.6. Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1. Overview, Historic and Forecast Sales Analysis
  • 9.4.2. Europe by Segment Sales Analysis
  • 9.4.3. Europe by Country Sales Analysis
  • 9.4.4. United Kingdom Sales Analysis
  • 9.4.5. France Sales Analysis
  • 9.4.6. Germany Sales Analysis
  • 9.4.7. Italy Sales Analysis
  • 9.4.8. Russia Sales Analysis
  • 9.4.9. Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1. Overview, Historic and Forecast Sales Analysis
  • 9.5.2. Asia Pacific by Segment Sales Analysis
  • 9.5.3. Asia Pacific by Country Sales Analysis
  • 9.5.4. China Sales Analysis
  • 9.5.5. India Sales Analysis
  • 9.5.6. Japan Sales Analysis
  • 9.5.7. South Korea Sales Analysis
  • 9.5.8. Australia Sales Analysis
  • 9.5.9. Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1. Overview, Historic and Forecast Sales Analysis
  • 9.6.2. Latin America by Segment Sales Analysis
  • 9.6.3. Latin America by Country Sales Analysis
  • 9.6.4. Brazil Sales Analysis
  • 9.6.5. Argentina Sales Analysis
  • 9.6.6. Peru Sales Analysis
  • 9.6.7. Chile Sales Analysis
  • 9.6.8. Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1. Overview, Historic and Forecast Sales Analysis
  • 9.7.2. Middle East & Africa by Segment Sales Analysis
  • 9.7.3. Middle East & Africa by Country Sales Analysis
  • 9.7.4. Saudi Arabia Sales Analysis
  • 9.7.5. UAE Sales Analysis
  • 9.7.6. Israel Sales Analysis
  • 9.7.7. South Africa Sales Analysis
  • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE LARGE MOLECULE DRUG SUBSTANCE CDMO COMPANIES

• 10.1. Large Molecule Drug Substance Cdmo Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11 . COMPANY PROFILES OF LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

• 11.1. Top 10 Company Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Eurofins Scientific
  • 11.3.1. Company Overview
  • 11.3.2. Company Revenue
  • 11.3.3. Products
  • 11.3.4. Recent Developments
• 11.4. WuXi Biologics
  • 11.4.1. Company Overview
  • 11.4.2. Company Revenue
  • 11.4.3. Products
  • 11.4.4. Recent Developments
• 11.5. Samsung Biologics
  • 11.5.1. Company Overview
  • 11.5.2. Company Revenue
  • 11.5.3. Products
  • 11.5.4. Recent Developments
• 11.6. Catalent Inc.
  • 11.6.1. Company Overview
  • 11.6.2. Company Revenue
  • 11.6.3. Products
  • 11.6.4. Recent Developments
• 11.7. Rentschler Biopharma SE
  • 11.7.1. Company Overview
  • 11.7.2. Company Revenue
  • 11.7.3. Products
  • 11.7.4. Recent Developments
• 11.8. AGC Biologics
  • 11.8.1. Company Overview
  • 11.8.2. Company Revenue
  • 11.8.3. Products
  • 11.8.4. Recent Developments
• 11.9. Recipharm AB
  • 11.9.1. Company Overview
  • 11.9.2. Company Revenue
  • 11.9.3. Products
  • 11.9.4. Recent Developments
• 11.10. Siegfried Holding AG
  • 11.10.1. Company Overview
  • 11.10.2. Company Revenue
  • 11.10.3. Products
  • 11.10.4. Recent Developments
• 11.11. Boehringer Ingelheim
  • 11.11.1. Company Overview
  • 11.11.2. Company Revenue
  • 11.11.3. Products
  • 11.11.4. Recent Developments
• 11.12. Fujifilm Diosynth Biotechnologies
  • 11.12.1. Company Overview
  • 11.12.2. Company Revenue
  • 11.12.3. Products
  • 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Service (USD MN)
• Contract Manufacturing (Clinical, Commercial) Market Sales by Geography (USD MN)
• Contract Development (Cell Line Development, Process Development) Market Sales by Geography (USD MN)
• Analysis Market by Source (USD MN)
• Mammalian Market Sales by Geography (USD MN)
• Microbial Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis by End-user (USD MN)
• Biotech Companies Market Sales by Geography (USD MN)
• CRO Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Large Molecule Drug Substance Cdmo Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Large Molecule Drug Substance Cdmo Report
• Market Research Process
• Market Research Methodology
• Global Large Molecule Drug Substance Cdmo Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Service
• Market Attractiveness Analysis by Source
• Market Attractiveness Analysis by End-user
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Service (USD MN)
• Contract Manufacturing (Clinical, Commercial) Market Sales by Geography (USD MN)
• Contract Development (Cell Line Development, Process Development) Market Sales by Geography (USD MN)
• Global Market Analysis by Source (USD MN)
• Mammalian Market Sales by Geography (USD MN)
• Microbial Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by End-user (USD MN)
• Biotech Companies Market Sales by Geography (USD MN)
• CRO Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.